Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 19:ehaf1050.
doi: 10.1093/eurheartj/ehaf1050. Online ahead of print.

Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial

Caio A M Tavares  1   2 , Patricia O Guimarães  1 , Marcelo Franken  1 , Karla Santo  1 , Guy F A Prado  1 , Felipe M T Bezerra  1 , Vagner Madrini-Junior  1   2 , Willterson C Bandeira  1 , Délcio G S Junior  3 , Gabriela Montenegro  4 , Jose A R Forte  5 , Walter Alvarenga  6 , Fernando de Martino  7 , Marcos M Seki  8 , Jose F K Saraiva  9 , Jamil A Saad  10 , Adriano Caixeta  11 , João L de A A Falcão  12 , Weimar K S Barroso  13 , George C X Meireles  14 , Thiago B Dias  15 , Frederico Monfardini  1 , Silvia R L Assis  1 , José C Nicolau  2 , Andrei C Sposito  16 , Renato D Lopes  17 , Yoshinobu Onuma  18 , Marco Valgimigli  19 , Dominick J Angiolillo  20 , Patrick W J C Serruys  18 , Otavio Berwanger  21   22 , Fernando Bacal  1   2 , Pedro A Lemos  1
Affiliations

Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial

Caio A M Tavares et al. Eur Heart J. .

Abstract

Background and aims: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention in patients with acute coronary syndrome remains uncertain. This analysis examined the temporal patterns of ischaemic and bleeding risks of early aspirin withdrawal compared with DAPT.

Methods: NEO-MINDSET randomized 3410 acute coronary syndrome patients undergoing successful percutaneous coronary intervention with drug-eluting stents within 4 days of hospital admission to either potent P2Y12 inhibitor monotherapy (prasugrel or ticagrelor) or standard DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. This prespecified landmark analysis examined early (0-30 days) and late (31-365 days) follow-up events. Co-primary outcomes were (i) the composite of all cause death, myocardial infarction, stroke, or urgent target-vessel revascularization (ischaemic outcome) and (ii) Bleeding Academic Research Consortium type 2, 3, or 5 bleeding.

Results: At 30 days, the composite ischaemic outcome occurred in 3.3% of patients receiving monotherapy vs 1.8% with DAPT (risk difference 1.5%, 95% confidence interval .4%-2.6%; P = .006). Bleeding occurred in .6% vs 1.5% (risk difference -.8%, 95% confidence interval -1.5%-.1%; P = .018). In the landmark analysis between Days 31 and 365, ischaemic outcome rates were similar between study groups (3.8% each; P = .977), while bleeding remained less frequent with monotherapy (1.3% vs 3.5%; risk difference -2.2%, 95% confidence interval -3.2%-1.1%; P > .001).

Conclusions: This prespecified 30-day landmark analysis suggests an excess of ischaemic risk with monotherapy vs DAPT in the first 30 days but not thereafter, whereas an aspirin-free strategy was consistently associated with fewer bleeding events within and after 30 days.

Keywords: Acute coronary syndrome; Antiplatelet monotherapy; Aspirin-free.

PubMed Disclaimer

LinkOut - more resources